Therefore, activating the cGAS-STING pathway through POLE mutations may help improve the survival of patients with endometrial cancer, and the stimulation of intrinsic immunity in cancer cells by POLE mutations provides a theoretical basis for personalized treatment of malignant tumors (Figure 2). The gene discussed is STING1; the disease is endometrial cancer.